SIGA Technologies Inc

SIGA Technologies Inc maintains a strong liquidity position, with $143.9 million in cash and equivalents and no long-term debt, resulting in a debt-to-equity ratio of 0.0 and a current ratio of 3.05. The company's price-to-book ratio of 1.85 and price-to-tangible-book ratio of 1.85 suggest a moderate premium to its book value, while its market cap of $305.5 million reflects a price-to-earnings ratio of 29.73. Profitability metrics indicate a return on equity of 6.23% and a return on assets of 4.23%, both below the typical thresholds for high-margin pharmaceutical firms. Operating income of $11.3 million and net income of $10.3 million for the period suggest a relatively lean profit margin, with gross profit of $22.2 million on $25.4 million in revenue. Geographically and segment-wise, SIGA's revenue concentration is not disclosed in the available data, but the company operates primarily in the pharmaceuticals industry, with a focus on antiviral therapies. The absence of segment-specific revenue breakdowns limits visibility into geographic or product diversification. Growth expectations are mixed. While the company reported a net income of $10.3 million, its operating cash flow was negative at -$6.1 million, and free cash flow was $10.4 million. Analysts estimate a mean revenue of $66.3 million for the next period, compared to the actual $25.4 million in the latest period, indicating a potential decline. Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no long-term debt and a high cash balance, but its operating cash flow is negative, which could affect long-term sustainability. No dilution sources were identified in the latest filings. Recent events include the continued commercialization of TPOXX, which is approved by the FDA for the treatment of smallpox. The company has not disclosed any major new product launches or regulatory changes in the latest filings, but its ESG controversies score of 100.00 indicates no recent controversies.